Thomas Dayspring/LinkedIn
Sep 15, 2026, 17:32
Thomas Dayspring: MHT for Vasomotor Symptoms May Also Offer Cardiovascular Benefits
Thomas Dayspring, Lipid Specialist, Educator at Early Medical, shared a post on LinkedIn about a recent article by Ziyuan Wang et al, published in JAMA Internal Medicine, adding:
“Important study:
MHT for the right woman is an excellent therapy – but it is not a CV or lipid-modulating therapy per se. But when used as indicated for vasomotor symptoms in peri- and early menopause it seems some CV benefit will follow.”
Title: Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women With Vasomotor Symptoms
Authors: Ziyuan Wang, Sonja A. Swanson, Maria M. Brooks, Emma Barinas-Mitchell, Marnie Bertolet, Jared W. Magnani, Rebecca C. Thurston, Samar R. El Khoudary
Other posts featuring Thomas Dayspring on Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke